Investment Rating - The report maintains a "Buy" rating for the company [1][10] Core Insights - The company received FDA breakthrough device designation for its self-expanding drug-coated stent system, marking a significant milestone as the first product of its kind for intracranial atherosclerotic stenosis treatment [3] - The company reported a revenue of 240 million yuan in the first half of 2025, reflecting a year-on-year growth of 12.53%, and a net profit attributable to shareholders of 14 million yuan, up 296.54% year-on-year [9] - The company is actively expanding its coronary intervention consumables both domestically and internationally, with successful participation in various procurement projects [9] Financial Projections - The total revenue is projected to reach 573.42 million yuan in 2025, with a year-on-year growth of 25% [1] - The net profit attributable to shareholders is expected to be 31.41 million yuan in 2025, showing a significant increase of 1,997.13% compared to the previous year [1] - The earnings per share (EPS) is forecasted to be 0.08 yuan in 2025, with a price-to-earnings (P/E) ratio of 433.13 based on the current market price [1][10]